Board summary
Key figures
84,760
Registered population
56.9% aged 18–64
21.4%
Aged 65+
ICB 19.9% · England 17.9%
6.9%
Ethnic minority (non-White)
2.7% Asian · England 9.6%
0.0%
In IMD quintile 1
ICB 17.1% · England 21.0%
0
Core20 residents (est.)
Resident basis; registered basis 0 · see page 3
13,115
Hypertension register
+5.84% in 3 yrs · England +5.60%
643
SMI register
70.6% of Sevenoaks'
1,217
COPD register
Reviews +0.74% in 3 yrs
Forecast to 2030
15,299
Hypertension patients, 2030
+2,184 on today
65.7%
QRISK ≥20% on statins, 2030
+2.31pp over 3 yrs
6.3%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Annual asthma reviews trail England.
Annual reviews reached 61.3% (England 65.7%), leaving a scale indicator of about 1,900 unreviewed patients across the 4,945 register, which recall could address.
Preschool MMR second-dose coverage misses target.
Age 5 MMR2 coverage is 88.2%, below the 95.0% target by 6.8 pp and 7.3 pp behind first-dose uptake at 95.5%.
Strong blood pressure checks in SMI.
Across 70.6% of Sevenoaks's SMI register, 85.3% had an annual blood pressure check, above NHS Kent and Medway ICB (79.7%) and England (83.4%).
Population, age and ethnicity
A higher 21.4% share aged 65+ may increase PCN frailty and care demand
Across 84,760 registered patients, 21.4% (18,122) are aged 65+, above Sevenoaks (19.7%), the ICB (19.9%), and England (17.9%). Children aged 0-17 comprise 21.7% (18,381 patients), matching Sevenoaks (21.7%) and above the ICB (20.7%) and England (19.6%). Census data shows 93.1% are White (Sevenoaks 92.1%, ICB 88.6%, England 81.1%), with an ethnic minority share of 6.9%, including Asian residents at 2.7% (Sevenoaks 2.9%, ICB 4.7%, England 9.6%). These dual cohorts may increase concurrent demand for frailty support and paediatric services, though Census resident bases differ from GP registers.
Age profile
65+: ICB 19.9%, England 17.9%
Ethnicity
Older people · falls rows are Sevenoaks local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Sevenoaks LA) | 2,262 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 81.5% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 59.6% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Sevenoaks LA) | 1,154 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Sevenoaks LA) | 15.5 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
No registered patients live in Core20 areas, with average deprivation at decile 7.5
Sevenoaks PCN records an average IMD decile of 7.5 (Sevenoaks 6.7, NHS Kent and Medway ICB 5.4, England 5.5), with 0.0% of registered patients in Core20 areas (Sevenoaks 4.4%, NHS Kent and Medway ICB 17.1%, England 21.0%). Practice averages range from decile 5.9 at Edenbridge Med Practice to 8.6 at South Park Medical Practice, yielding an estimate of 0 Core20 patients. Because area indices identify zero Core20 patients, inequalities outreach could focus on individual inclusion health and vulnerable clinical cohorts.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
643
SMI register
0.75% recorded prevalence
300
Learning disability register
0.35% recorded prevalence
22
Care homes, 1,173 beds
In the PCN catchment
8.7%
Provide unpaid care
Sevenoaks, Census 2021
The PCN records 643 severe mental illness patients (70.6% of the borough) and 300 learning disability patients (69.1% of the borough; prevalence 0.3% vs England 0.6%). Catchment services include 22 care homes with 1,173 beds. Sevenoaks borough records an 8.7% unpaid care rate (PCN ceiling estimate 7,374) and 6 autumn 2025 rough sleepers. Lower recorded prevalence may reflect coding or case-finding differences, which practice register validation would test.
Severe mental illness: physical health checks
Across 643 SMI patients, 85.3% had a blood pressure check (England 83.4%) and 83.1% had a BMI check (England 82.1%). Over three years, BMI recording rose +3.3 pp (England +5.1 pp).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
13,115
Hypertension register
+5.84%
Register growth, 3 yrs
Sevenoaks +14.96% · England +5.60%
+2.14pp
BP control, under 80
≤140/90 · +0.33pp aged 80+
+2,184
More patients by 2030
Forecast 15,299 (17.10%)
Hypertension case-finding and control
Hypertension prevalence is 15.3% (13,115 patients), below Sevenoaks (16.6%) and NHS Kent and Medway ICB (16.2%), but in line with England (15.2%), though crude and not age-adjusted. Blood pressure control trails comparators: 64.2% of hypertensive patients under 80 are controlled to <= 140/90 mmHg (Sevenoaks 64.1%, ICB 64.6%, England 67.8%), while 76.9% aged 80+ meet <= 150/90 mmHg (Sevenoaks 77.9%, ICB 78.3%, England 81.2%), and overall control reaches 67.4% (Sevenoaks 68.0%, ICB 67.7%, England 70.3%). With blood pressure control below national rates, the PCN could prioritise systematic recall audits and treatment titration for uncontrolled hypertensive patients.
Lipids and statins
Uptake of lipid-lowering therapy is 60.8% for QRISK >= 20% (Sevenoaks 60.3%, ICB 61.4%, England 63.6%), 65.1% in CKD (Sevenoaks 64.6%, England 70.3%), and 69.5% in diabetes without CVD (England 73.2%). Fewer at-risk patients receive lipid-lowering therapy than England rates, indicating an opportunity to prioritise primary-prevention statin recall audits.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 147,643 | £1.70 | £1.90 | £1.86 | £250,993 |
| Cardiovascular (all), 2025 | 189,751 | £2.66 | £3.57 | £3.33 | £504,738 |
In 2026, lipid-regulating drugs accounted for 147,643 items at £1.70 per item (Sevenoaks £1.68, England £1.86, ICB £1.90), spending £23,623 less than at England's unit cost. This unit-cost indicator reflects lower expenditure per item than national rates, though unit cost does not evaluate prescribing efficiency or patient case-mix.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+6.31%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+0.57%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 6.1% (4,945 patients; Sevenoaks 6.1%, England 6.6%). Annual reviews reached 61.3% (England 65.7%), leaving about 1,900 patients unreviewed. COPD prevalence is 1.4% (1,217 patients; England 1.9%), with 3-year change of -1.7% (England +2.6%) and an unadjusted benchmark gap of +171 to +389 patients. Annual COPD reviews reached 72.8% (England 76.4%). Slower review rates may reflect recall gaps, which practice audits could test.
Cancer register and children's immunisation
Cancer prevalence is 5.1% (4,361 patients), above England (3.8%). In childhood immunisation, 6-in-1 uptake at 12 months reached 95.3% and age 5 MMR dose 1 reached 95.5%, both meeting the 95.0% target. However, age 5 MMR dose 2 drops to 88.2%, below the 95.0% target by 6.8 pp and reflecting a 7.3 pp second-dose drop-off. Timely primary uptake is not sustained for preschool boosters.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Kent and Medway ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,630
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Kent and Medway ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 82.1% | 85.4% | 23% | 1,509 |
| Prostate | 54.4% | 53.2% | 37% | 1,435 |
| Lung | 29.4% | 33.8% | 21% | 1,109 |
| Bowel | 48.2% | 47.0% | 29% | 1,013 |
| Skin cancer | 87.5% | 87.8% | 23% | 562 |
In 2022, 55.6% of known-stage cancers across NHS Kent and Medway ICB were diagnosed at stage 1 or 2 (4,661 of 8,384; England 55.3%), below the 75.0% national ambition by 2028. Known-stage coverage was 63.6% (8,384 of 13,189; England 67.0%). Reaching the ambition requires about 1,630 (1,627) extra early-stage diagnoses annually across the ICB, with bowel (48.2%) and lung (29.4%) furthest behind. Sevenoaks PCN recorded 5.1% cancer prevalence (+11.3% over three years) and 74.4% cervical screening coverage (England 66.8%). Screening variation, including 63.0% cervical coverage at St John's Medical Practice, suggests practice recall audits could support earlier detection.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
For Maidstone and Tunbridge Wells NHS Trust, cancer performance was 2.4 pp above the 85.0% 62-day referral to treatment standard, 6.8 pp above the 75.0% 28-day faster diagnosis standard, and 2.3 pp above the 96.0% 31-day combined treatment standard. Across NHS Kent and Medway Integrated Care Board, 62-day referral to treatment and the 31-day combined standard trailed their standards, while the 28-day faster diagnosis standard was 1.8 pp above 75.0%. Timely acute trust access provides strong local pathway support, though wider ICB backlogs could create cross-boundary referral friction.
| Pathways within standard (%) | Maidstone and Tunbridge Wells | King's College | Dartford and Gravesham | Kent and Medway ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 81.78 | 80.68 | 78.14 | 76.78 | 79.32 |
| 31-day treatment (96%) | 98.35 | 96.68 | 97.48 | 95.84 | 92.50 |
| 62-day referral to treatment (85%) | 87.43 | 70.15 | 63.59 | 75.93 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Maidstone and Tunbridge Wells | King's College | Dartford and Gravesham | England |
|---|---|---|---|---|
| MRI | 0.92 | 21.22 | 0.36 | 21.40 |
| CT | 0.51 | 22.60 | 2.08 | 9.92 |
| Echocardiography | 2.57 | 14.39 | 3.90 | 28.48 |
| Colonoscopy | 19.80 | 41.81 | 0.40 | 30.83 |
| Gastroscopy | 24.03 | 35.98 | 0.00 | 29.02 |
| All 15 DM01 tests | 6.42 | 19.15 | 8.37 | 23.14 |
| Community services activity | Kent residents | Kent and Medway ICB |
|---|---|---|
| Care contacts | 210,170 | 254,055 |
| Referrals | 59,360 | 68,085 |
| Patients with a contact | 60,605 | 72,060 |
Community services (residents of Kent), Jun 2026 (provisional). In Sevenoaks borough (wider system, not PCN level), adults aged 65 and over accounted for 65.8% of all community service contacts among borough residents, representing 138,250 of 210,170 total contacts in the provisional June 2026 dataset. This borough-level activity reflects high community care usage among older residents.
Practice variation and patient experience
Patient experience varies by 22.4 pp while vaccination achievement spans 78.4 pp
In 2025/26, overall QOF achievement was 92.5% in England. Practice achievement ranged from 76.7% at St John's Medical Practice to 99.3% at South Park Medical Practice. Vaccination and immunisation achievement varied by 78.4 pp, with Town Medical Centre recording 15.6% (England 55.2%) and South Park Medical Practice achieving 94.0%. Practice audits would test whether variation reflects recall differences.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Town | 104 | 0.0 | 75.0% | 78.9% | 89.9% |
| Borough Green | 116 | 0.0 | 73.9% | 51.7% | 88.5% |
| Amherst Medical | 103 | 0.0 | 59.6% | 70.2% | 86.4% |
| Edenbridge Med | 99 | 0.0 | 45.1% | 77.4% | 85.4% |
| South Park | 99 | 0.0 | 50.1% | 70.7% | 70.1% |
| Westerham Practice | 114 | 0.0 | 56.3% | 74.3% | 69.9% |
| Otford Medical | 99 | 0.0 | 59.5% | 69.7% | 69.2% |
| St John's Medical | 127 | 0.0 | 40.2% | 64.5% | 67.5% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Twelve of 25 tracked three-year trends trail England despite diabetes control gains
Across 25 tracked three-year trends, 12 trail England. The largest lags are learning disability prevalence (-0.7% vs England +5.4%) and COPD prevalence (-1.7% vs England +2.6%), alongside slower growth in annual heart failure reviews (+4.1% vs England +8.7%). Conversely, non-frail diabetes HbA1c control improved +10.3% (England +4.4%), reaching 59.6% (2,125 of 3,563 patients), and asthma reviews rose +6.3% (England +4.4%). Diverging trajectories show management gains are achievable, which practice recall audits would test when addressing cardiovascular and respiratory review lags.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Learning disability register
Heart failure reviews
COPD register
QRISK statin treatment
COPD reviews
Diabetes HbA1c control
Asthma reviews
Diabetes statin (no CVD)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Sevenoaks | Asset | PCN | Sevenoaks |
|---|---|---|---|---|---|
| Care homes (catchment) | 22 (1,173 beds) | n/a | Schools (catchment) | 93 | n/a |
| Children's centres | 3 | 5 | Places of worship | 87 | 86 |
| Libraries | 9 | 11 | Day centres (VCS) | 3 | 11 |
| Children and young people (VCS) | 1 | 2 | Carers support groups (VCS) | 2 | 3 |
| Primary schools (LA maintained) | 26 | 24 | Primary academies | 8 | 12 |
| Special schools | 2 | 1 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Preschool MMR second-dose recall
Age-5 MMR2 coverage is 88.2% across 220 children (6.8 pp below the 95.0% target; 7.3 pp below MMR1 at 95.5%), with drops of 35.8 pp at Town Medical Centre and 15.8 pp at St John's Medical Practice. Low cost, quick to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Option 2
Structured annual asthma review recall
Annual asthma reviews reached 61.3% (Sevenoaks 58.8%, ICB 60.4%, England 65.7%) across the 4,945 register (prevalence 6.1%), leaving a scale indicator of 1,915 (about 1,900) unreviewed patients. For discussion: the PCN could run a single asthma review template alongside inhaler prescribing checks and offer after-school or holiday review slots. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 3
COPD register validation and recall
COPD prevalence is 1.4% (1,217 patients) vs Sevenoaks 1.6% and England 1.9% (3-year change -1.7% vs England +2.6%), an unadjusted gap of +171 to +389; annual reviews are 72.8% (England 76.4%). Moderate effort to run.
Evidence base: the copd register is the cohort for spirometry-confirmed diagnosis, annual review and inhaler technique; register size and growth set the workload those interventions must cover.
Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Inclusion health outreach targeting (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI health check review (p4) | Record of BMI in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Hypertension control recall audit (p5) | Last BP reading of patients (80+ yrs with hypertension) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Preschool booster recall review (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Practice telephone access review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Preschool MMR second-dose recall (p12) | MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Option 2 · Structured annual asthma review recall (p12) | Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 3 · COPD register validation and recall (p12) | COPD register · COPD: QOF prevalence · COPD patients with a review in the last 12 months | Core20PLUS5 approach · Tobacco and Vapes Bill | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
